These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 25519824

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.
    Derosa L, Galli L, Orlandi P, Fioravanti A, Di Desidero T, Fontana A, Antonuzzo A, Biasco E, Farnesi A, Marconcini R, Francia G, Danesi R, Falcone A, Bocci G.
    Cancer; 2014 Dec 15; 120(24):3923-31. PubMed ID: 25111199
    [Abstract] [Full Text] [Related]

  • 3. Metronomic therapy in metastatic castrate-resistant prostate cancer: Experience from a tertiary cancer care center.
    Dabkara D, Ganguly S, Biswas B, Ghosh J.
    Indian J Cancer; 2018 Dec 15; 55(1):94-97. PubMed ID: 30147102
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.
    Podrazil M, Horvath R, Becht E, Rozkova D, Bilkova P, Sochorova K, Hromadkova H, Kayserova J, Vavrova K, Lastovicka J, Vrabcova P, Kubackova K, Gasova Z, Jarolim L, Babjuk M, Spisek R, Bartunkova J, Fucikova J.
    Oncotarget; 2015 Jul 20; 6(20):18192-205. PubMed ID: 26078335
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.
    Hussain M, Rathkopf D, Liu G, Armstrong A, Kelly WK, Ferrari A, Hainsworth J, Joshi A, Hozak RR, Yang L, Schwartz JD, Higano CS.
    Eur J Cancer; 2015 Sep 20; 51(13):1714-24. PubMed ID: 26082390
    [Abstract] [Full Text] [Related]

  • 9. Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.
    Petrylak DP, Gandhi JG, Clark WR, Heath E, Lin J, Oh WK, Agus DB, Carthon B, Moran S, Kong N, Suri A, Bargfrede M, Liu G.
    Invest New Drugs; 2015 Apr 20; 33(2):397-408. PubMed ID: 25556680
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Metronomic chemotherapy with cyclophosphamide plus low dose of corticosteroids in advanced castration-resistant prostate cancer across the era of taxanes and new hormonal drugs.
    Calvani N, Morelli F, Naglieri E, Gnoni A, Chiuri VE, Orlando L, Fedele P, Cinieri S.
    Med Oncol; 2019 Aug 09; 36(9):80. PubMed ID: 31399784
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer.
    Zhou T, Zeng SX, Ye DW, Wei Q, Zhang X, Huang YR, Ye ZQ, Yang Y, Zhang W, Tian Y, Zhou FJ, Jie J, Chen SP, Sun Y, Xie LP, Yao X, Na YQ, Sun YH.
    PLoS One; 2015 Aug 09; 10(1):e0117002. PubMed ID: 25625938
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
    Pond GR, Armstrong AJ, Galsky MD, Wood BA, Leopold L, Sonpavde G.
    Urol Oncol; 2013 Nov 09; 31(8):1457-63. PubMed ID: 22552048
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of maintenance therapy with a nonspecific cytochrome P17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer.
    Gil-Bazo I, Arévalo E, Castillo A, Zudaire ME, Carranza OE, Fusco JP, Castañón E, Collado-Gómez V, López I, Gil-Aldea I.
    Clin Genitourin Cancer; 2013 Jun 09; 11(2):78-84. PubMed ID: 23260990
    [Abstract] [Full Text] [Related]

  • 20. [Metronomic chemotherapy with oral cyclophosphamide : An individual option for the metastatic castration-resistant prostate cancer patient?].
    Knipper S, Mandel P, V Amsberg G, Strölin P, Graefen M, Steuber T.
    Urologe A; 2019 Apr 09; 58(4):410-417. PubMed ID: 29808369
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.